PFO
NKTR icon

Pathstone Family Office’s Nektar Therapeutics NKTR Stock Holding History

Pathstone Family Office’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-944
Closed -$9.95K – 1291
2023
Q1 		$9.95K Sell
944
-1,601
-63% -$48.4K ﹤0.01% 1188
2022
Q4 		$86.1K Buy
+2,545
New +$123K ﹤0.01% 1448

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Pathstone Family Office's NKTR Position: Q2 2023 in Review

Pathstone Family Office sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 944 shares — an estimated $9.95K sold.

Pathstone Family Office first reported a position in NKTR in Q4 2022 and held it in 2 quarters. The position peaked at $86.1K in Q4 2022. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Pathstone Family Office reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Pathstone Family Office sold 944 Nektar Therapeutics shares in Q2 2023, an estimated $9.95K.
  • Pathstone Family Office first reported a position in Nektar Therapeutics in Q4 2022 and held it in 2 quarters.
  • Pathstone Family Office's Nektar Therapeutics position peaked at $86.1K in Q4 2022.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Pathstone Family Office's 13F filing for Q2 2023, filed 14 Aug 2023.